Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
89.82
-0.96 (-1.06%)
At close: Oct 12, 2026, 4:00 PM EDT
89.08
-0.74 (-0.83%)
After-hours: Oct 12, 2026, 4:05 PM EDT
Rhythm Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 18 analysts polled by S&P Global, Rhythm Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $138.88. The average 1-year stock price forecast is 54.62% higher than the current stock price, while the lowest is $105 (+16.90%) and the highest is $160 (+78.13%).
Price Target: $138.88 (+54.62%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Rhythm Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 10 | 10 | 11 | 11 |
| Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Hold | 1 | 1 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 17 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $105 → $130 | Buy | Reiterates | $105 → $130 | +44.73% | Oct 12, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Oct 9, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $155 → $159 | Buy | Reiterates | $155 → $159 | +77.02% | Oct 8, 2026 |
| Wolfe Research | Wolfe Research | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Sep 17, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 16, 2026 |
Financial Forecast
Revenue This Year
315.08M
from 189.76M
Increased by 66.04%
Revenue Next Year
565.19M
from 315.08M
Increased by 79.38%
EPS This Year
-3.07
from -3.11
EPS Next Year
-0.53
from -3.07
EPS and Forward PE are based on non-GAAP adjusted numbers.